Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pyrotinib plus trastuzumab for HER2-positive early or locally advanced breast cancer
ChiCTR2000038503Phase 2Not yet recruiting
- Sponsor
- Ganzhou Cancer Hospital
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and trastuzumab in breast cancer, sponsored by Ganzhou Cancer Hospital. Primary endpoint: invasive disease-free survival. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
pyrotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000038503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038503.